Athersys, Inc. (NASDAQ:ATHX) announced interim results from the Phase 2 clinical study of the administration of Athersys’ MultiStem(R) cell therapy to treatment refractory ulcerative colitis (UC) patients being conducted by Pfizer, Inc. The study results demonstrate favourable safety and tolerability for MultiStem through 8 weeks following treatment. Athersys, Inc. (NASDAQ:ATHX) shares after opening at $1.27 moved to $1.33 on last trade day and at the end of the day closed at $1.33. Company price to sales ratio in past twelve months was calculated as 42.73 and price to cash ratio as 3.21. Athersys, Inc. (NASDAQ:ATHX) showed a negative weekly performance of -52.33%.
OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) plunged more than 60 percent on Monday as a phase III trial evaluating its drug candidate Custirsen for metastatic castrate-resistant prostate cancer failed to meet the primary endpoint of a statistically significant improvement in overall survival. OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) shares fell -60.31% in last trading session and ended the day on $3.85. OGXI return on equity ratio is recorded as -65.90% and its return on assets is -48.70%. OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) yearly performance is -62.25%.
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) will host a conference call on Tuesday, May 6, 2014, at 4:30 p.m. ET. During the call, management will review the company’s first quarter 2014 financial results and provide an update on Infinity’s business. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) shares moved up 0.21% in last trading session and was closed at $9.36, while trading in range of $8.72 – $9.67. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) year to date (YTD) performance is -32.22%.
On April 15, 2014, Verastem, Inc. (NASDAQ:VSTM) entered into a lease agreement with Intercontinental Fund III 117 Kendrick Street, LLC, as landlord, for approximately 15,197 square feet of space at 117 Kendrick Street in Needham, Massachusetts (the “Lease Agreement”). Verastem Inc. (NASDAQ:VSTM) weekly performance is -11.75%. On last trading day company shares ended up $8.04. Verastem Inc. (NASDAQ:VSTM) distance from 50-day simple moving average (SMA50) is -32.65%. Analysts mean target price for the company is $22.56.
Leave a Reply